% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

biotekker 156 posts  |  Last Activity: 17 hours ago Member since: Jul 10, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Forbes blog

    by retiredceo2002 22 hours ago
    biotekker biotekker 17 hours ago Flag

    A substantial portion of Forbes' revenue is from "article for hire schemes" like this one. It should be illegal and possibly is, but it is how the world has become. Pay to play!

  • Reply to

    Relax, The FDA will grant NCE

    by mariospazian52 23 hours ago
    biotekker biotekker 17 hours ago Flag

    There are some very powerful, rich and corrupt people who are deadset on destroying AMRN. This was evident in their FDA hearing that was closer to a sham show trial than anything else. The next move was to delay NCE as long as possible and let AMRN starve.

    Even with the ruling, today's complete fabrication of a news article by Forbes proves that those same corrupt players are still deadset on AMRN's destruction.

    Just remember, you can be right.....and still go broke. Be very careful here.

  • Reply to

    So sad how one man can ruin it for millions

    by andrelee1974 May 28, 2015 2:36 PM
    biotekker biotekker May 28, 2015 3:30 PM Flag

    Not true.

    If the CEO never would have spouted the lie to the world then the LIGHT study would still be running and on pace to finalize in 2017 instead of now 2022 and it would have saved OREX around 100 million in direct study expenses and you wouldn't have doctors who will now be worried about prescribing the drug due to this higher Contrave death rate.

    Share price is unknowable but it most probably would be higher than here.

  • biotekker biotekker May 21, 2015 3:06 PM Flag

    Doctors are going to make the exact same health determination as you when determining whether to continue to prescribe Contrave or begin prescribing it. They will not be risking their patients health and will be moving to other less risky prescription avenues for their patients going forward.

    This is why OREX is a sell here. Growth just ended and now it is far overvalued in mkcap.

    Sentiment: Sell

  • biotekker by biotekker May 21, 2015 1:32 PM Flag

    Just a warning to all. The data from the study was virtually the same as the control and this tiny company reeks of classic scam pump and dump. Not conclusive yet but very suspect so IMO all longs should be taking all profits here.

    Your Welcome.

    Sentiment: Sell

  • biotekker biotekker May 20, 2015 4:53 PM Flag

    alcuomo881 You are looking at shedding which isn't primary. The vaccine cant be approved unless it shows an actual clinical benefit that is significant and provable which is testing lesions. In lesion reduction (real world results), GNCA's best performing formulation actually did WORSE than placebo in reducing lesions.

    Ironically, taking a GNCA placebo drug reduced lesions better than getting GNCA's vaccine candidate.

  • biotekker biotekker May 20, 2015 4:42 PM Flag

    The other issue is someone should notify the SEC to go check the ID's of everyone who bought large amounts of GNCA starting 2 days ago on May 18th, 19th, and also May 15th when it was at $9.20 when GNCA abruptly started moving straight up! Then shockingly new study results come out.

    I guarantee you in the big buyers on the 18th there is a connection to a GNCA or study insider who leaked that these results were about to come out. And given the usual low volume it would not be difficult to ID and track back all the culprits either.

  • So that means that the drug performed less than placebo.

    The FDA will never accept that. They need to change and maybe test avg lesion duration as another clinical endpoint in hopes that it can be testable there because the FDA will never accept the placebo doing better than the drug itself on the primary clinical endpoint.

    If any PIII showed these results the stock would get crushed.

  • 1. Both are a combo of generics and thus always will face lower priced generic competition. Strongly limiting any upside in sales.

    2. Both have similar prescription levels but OREX get's exponentially less money per script due to much lower margins and the revenue sharing with Takeda.

    3. Both have pretty severe side effects but OREX works only half as good as VVUS's drug in losing weight.

    4. Both had a very high institutional adoption before and shortly after launch. Now VVUS has lost all those Funds and it dropped 80% as they left; now OREX is primed to do a similar drop as the Funds exit OREX as well. This let's us see the future price point for OREX just by watching the Hedge Funds.

    5. Both are being sued by big time generic drug manufacturers and their control of the patents are being challenged.

    6. But while their products and sales are so similar, OREX still sports 3X the mkcap of VVUS, even with VVUS having a backup drug on the market and OREX having the risk of only a single generic product to justify their entire large mkcap.

    Prediction: Over the next few months OREX will make a similar percentage move down as VVUS did when the VVUS pump ended. Just look at the old VVUS chart to see what is coming for OREX as the large fund ownership exits.

    Sentiment: Sell

  • Reply to

    4.85 today, in the 4.50's next week

    by tr776t5 May 18, 2015 10:02 AM
    biotekker biotekker May 18, 2015 10:54 AM Flag

    That's about right for this week.

    Then comes the following Wednesday-Friday when the first full week of scripts come back where Doctors AND Patients are both aware that Contrave not only does zero for the heart, it very well may raise your risk of Death as well; and as such they quit prescribing it and Contrave's scripts begin to drop. That's when the move into the 3's is possible.

    Study Notes:
    118 Deaths from actively taking Contrave patients vs 102 Deaths from placebo taking patients.

    29 additional complaints of chest pain from Contrave users, 25 for placebo.

    26 Non CV Contrave deaths and 17 Non CV placebo deaths.

  • biotekker biotekker May 16, 2015 1:34 PM Flag

    I'd venture that in the best case scenario Orex will pay 100 million for their half of the new trial, plus have to pay back Takeda 100 million for the money Takeda has already spent for the canceled trial that OREX ruined by sharing false 25% data with over 100 people AND by publishing a false patent to the entire planet. At the current run rate that's about 4 years worth of OREX revenues lost that aren't in the analysts estimates. And that's the best case scenario.

    If Takeda decides its not worth their time or money even with OREX paying an extra 100 million, then OREX is legitimately screwed in that scenario as well.

    Sentiment: Sell

  • Reply to

    How much did new scripts drop this week?

    by tr776t5 May 15, 2015 2:43 PM
    biotekker biotekker May 15, 2015 4:42 PM Flag

    NOPE! About flat. up only 120 scripts. But next week and certainly the last week of the month is when the negative prescription growth will hit and the real fireworks will begin with the hundreds of millions of institutional shares cramming for the exits.

    Sentiment: Sell

  • You know who I'm speaking of. The guy who obsessively posts over and over again the same junk headline "Contrave...a dangerous (!) double-generic (!) drug cocktail (!) !!!"

    Well it seems he's atleast partly right after all.

    It is clear now that Contrave does absolutely nothing for the heart and it may very well actually increase your chances of dying given that the Contrave group had 119 deaths and the Placebo group had 114 deaths. And it get's even scarier when you throw out those who quit participating in the study by not taking the study drug. Once you control for those people, the same amount on both sides, Contrave had 118 deaths and Placebo only 102 deaths!

    That's 16% more deaths in the Contrave group than in the Placebo group so that crazy dude actually got lucky and might be right. Further, when they review the totality of the data which is more than 50%, we might have have a statistically significant higher death risk for Contrave. Too bad the study was ruined by the CEO.

    No wonder the CEO only wanted to talk about the 25% and then wants to cancel the study from actual completion and delayed the 50% data for as long as he possibly could.

    Sentiment: Sell

  • Reply to


    by boilerroommanager May 15, 2015 1:48 PM
    biotekker biotekker May 15, 2015 1:55 PM Flag

    FULLY AGREE WITH YOU! It was those leaks to hedge funds of the early 25% data in 2014 that caused the funds to go VERY LONG OREX in 2014 and explains why they are stuck BIG TIME LONG today and also explains why OREX went up from the 3's and 4's to these very high prices in the first place. They tried to cheat and front run all of retail because the OREX CEO cheated and leaked insider study information to them, but now that insider information has been proven 100% FALSE!! AND THEY ARE NOW TRAPPED!

    But they still committed illegal acts by front running with insider info and still deserve jail time.

  • The plan is to ALL PUMP OREX together so they can all transfer their bagholding to RETAIL (thats you and me) but in that game you benefit the most by being the first to sell out and the last fund holding gets screwed like retail.

    Very Funny watching this game of musical chairs with retail.

  • Its so clear as day how corrupt wallstreet is with all those analysts who are now caught investing on the wrong horse. So silly seeing them pay for fake article after fake article trying to convince people OREX isn't done for.

    Saw this exact same thing with VVUS 2 years ago when it was at 20 per share on its way down to $2/share. They were pumping VVUS the entire time they were liquidating their VVUS holdings. Same thing is now going to happen with OREX.

    I guarantee it!

    Sentiment: Sell

  • biotekker biotekker May 14, 2015 9:55 PM Flag

    You don't think a study drug can kill you via a stroke if it is known to raise blood pressure? Strokes and many other forms of death that can be caused by drugs are all Non-CV deaths. that doesn't mean they shouldn't be considered when assessing a drugs safety.

  • biotekker biotekker May 14, 2015 6:19 PM Flag

    The result is this. When you control for and remove patients who quit taking the study drug in both the contrave and the placebo groups. You get this amount of deaths from the PURE Contrave group, 118 deaths and from the PURE placebo drug group, 102 deaths.

    Looks like if this study were allowed to continue that it may have proven an increased death risk by taking Contrave.

  • Reply to


    by biotekker May 13, 2015 4:57 PM
    biotekker biotekker May 14, 2015 6:12 PM Flag

    Dr. Nissen-- "the results at the 50 percent time point include 114 deaths in the placebo group vs. 119 deaths in the Contrave group (HR=0.95, 95 percent CI 0.74 – 1.23)."

    And the data gets even worse. So here we know for a fact that already more people died in the Contrave group than the placebo. But whats even worse is that many people simply quit taking their study drug and when you remove those non compliant patients the death rates are as follows:

    102 deaths in the placebo group vs 118 deaths in the Contrave group!!!!! That is out of nearly 9,000 patients over 2 years, you have a near 20% greater chance of dying when you take Orex's weightloss drug to lose weight! 20%! A weightloss drug is supposed to help you live, not die.

    Now you know why the OREX CEO wanted to sabotage the study by sharing the 25% results with so many people. He didn't want the study results to become final and sink his companies only product.

    Sentiment: Sell

  • biotekker biotekker May 14, 2015 5:44 PM Flag

    Dr. Nissen-- "the results at the 50 percent time point include 114 deaths in the placebo group vs. 119 deaths in the Contrave group (HR=0.95, 95 percent CI 0.74 – 1.23)."

    MORE DEATHS IN CONTRAVE GROUP. And surprisingly, if a Contrave patient quit taking the study drug, their survivability went up 53% by QUITTING CONTRAVE. No wonder OREX wanted this study halted as it might have proven that Contrave does raise your death risk.

    Sentiment: Sell

2.47-0.03(-1.20%)May 29 4:00 PMEDT